How research paved the way for progress in a rare form of ALS

An experimental ALS drug that grew out of basic and clinical research at Columbia University's Vagelos College of Physicians and Surgeons may soon become available for patients with a rare and aggressive form of the disease.

Brepocitinib yields improvements in cutaneous sarcoidosis

For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting ...

page 11 from 27